This website is meant to serve as a resource for all families affected by ADLD as a source of information, resources, and community as research teams across the world work towards a path to a disease-modifying therapy. We are so grateful for every team and individual for the work they are doing.
Everything a family member needs to understand — the disease, the inheritance, and the window we're working with.
ADLD (Autosomal Dominant Leukodystrophy) is caused by an extra copy of the LMNB1 gene, which makes the body overproduce a protein called Lamin B1. Over decades, this destroys myelin — the protective coating around nerve fibers. The result is a slow loss of neurological function beginning in mid-adulthood. It is extremely rare: fewer than 50 families have been documented worldwide.
ADLD progresses extremely slowly. MRI changes begin a decade or more before symptoms appear. This long pre-symptomatic window is why there is genuine hope: it creates time for a therapy to arrive and be given before meaningful damage accumulates.
Right now, there is a 50% chance of carrying the mutation. This is not a diagnosis — it's a prior probability based on one parent being a confirmed carrier.
Genetic testing via MLPA or chromosomal microarray can resolve this to near-certainty. A negative result means no mutation, no risk.
A positive result means confirmed carrier status — and access to clinical trials, monitoring programs, and the interventions being developed right now.
For families carrying the LMNB1 mutation, the research landscape in 2026 is fundamentally different from what it was in 2016 or even 2020. Three things have converged: (1) the first human clinical trial of a targeted therapy is actively underway at Mayo Clinic, (2) a natural history study with 35 enrolled participants is building the data infrastructure needed for expanded trials, and (3) the ASO technology platform being used for ADLD has already produced FDA-approved therapies for SMA and ALS. The science is not theoretical — it is in a human being's body right now.
"Broadly clinically available" means: accessible to confirmed carriers beyond the single N=1 trial participant. This includes enrollment in a Phase 2+ trial, expanded access programs, compassionate use authorization, or approved therapy. This is more achievable than full FDA approval and is the realistic pathway within 7–10 years.
According to GeneReviews and MedlinePlus, symptoms typically begin in the fourth to fifth decade of life (forties to fifties), meaning there may be 8–12 years of pre-symptomatic time remaining. The consensus from analogous rare disease programs is that pre-symptomatic treatment produces dramatically better outcomes than treatment after damage begins. Every year of lead time matters enormously.
Five independent programs worldwide are working toward a disease-modifying therapy for ADLD. Here is a complete picture of each.
A detailed breakdown of every team working on ADLD — from clinical trials and drug discovery to natural history studies and disease modeling. Some are developing therapies directly; others are building the scientific foundation that makes therapies possible.
An antisense oligonucleotide is a short, synthetic strand of nucleic acid — about 20 nucleotides long — engineered to bind to a specific messenger RNA sequence. nL-LMNB1-001 is designed to bind to the LMNB1 mRNA and trigger its degradation via a naturally occurring enzyme (RNase H). The result is a reduction in how much Lamin B1 protein the cell produces. It does not alter the underlying DNA — it works one level up, at the RNA layer, silencing the overexpressed gene without permanently editing the genome. It is delivered via intrathecal injection (directly into the cerebrospinal fluid space around the spinal cord), which allows it to reach the central nervous system and bypass the blood-brain barrier.
Ideally: confirmed LMNB1 mutation carriers in the pre-symptomatic phase. The earlier the intervention, the less demyelination has occurred and the more the therapy can preserve rather than restore function. Early symptomatic patients (autonomic dysfunction only, no motor symptoms) are also strong candidates. Patients with established motor or cerebellar symptoms may benefit from stabilization but are unlikely to see reversal of existing damage.
Based on comparable ASO therapies (nusinersen for SMA, tofersen for ALS): intrathecal injections administered at a clinical center, with a loading dose schedule (e.g., 4 doses over 2 months) followed by maintenance injections every 4–6 months indefinitely. Requires lumbar puncture under local anesthesia. Monitoring via MRI and CSF biomarkers at regular intervals.
A small molecule is a low-molecular-weight chemical compound — typically orally bioavailable — that interacts with cellular machinery to reduce gene expression. CID 662896 was identified through a screen of ~97,000 compounds and reduces LMNB1 protein levels in a dose-dependent manner. Critically, it has demonstrated blood-brain barrier penetration in mouse studies and has reduced Lamin B1 in ADLD patient-derived cell samples. The precise mechanism of action is still under investigation — the Padiath lab is characterizing exactly how it suppresses LMNB1 expression and ensuring it targets disease-relevant cell types (oligodendrocytes) in the CNS.
An oral drug that crosses the blood-brain barrier would be transformative compared to the ASO, which requires intrathecal spinal injection every 4–6 months at a clinical center. A pill-based therapy could be taken at home, dramatically improving accessibility, patient burden, and global reach — particularly important given how rare ADLD is and how geographically dispersed affected families are.
Same principles apply as the ASO: pre-symptomatic use is optimal. Because it would likely be oral and self-administered, compliance and long-term use in pre-symptomatic individuals is more feasible than with injection-based therapies. If approved, this could become the preferred long-term maintenance therapy for confirmed carriers.
ADLD is caused by a duplication of the LMNB1 gene — patients have one normal copy and one (or more) extra copies. Allele-specific silencing uses antisense technology to target and silence only the duplicated copy, leaving the normal copy intact and functional. This is a more refined approach than the Mayo ASO, which broadly reduces all LMNB1 expression. Published proof-of-concept in Brain (Giorgio et al., 2019) demonstrated selective suppression of the disease-causing allele in patient-derived cell models.
Lamin B1 is not just a disease gene — it has essential structural roles in every cell's nucleus. Broadly reducing all Lamin B1 (as the Mayo ASO does) carries a theoretical risk of affecting normal cellular function. Allele-specific silencing preserves the normal copy's activity, potentially producing a better safety profile and allowing more aggressive dosing. For patients who might be on therapy for decades, this distinction matters.
Same pre-symptomatic advantage as all ADLD therapies. The superior safety profile — if confirmed in animal and human studies — may make it particularly appropriate for very long-term use in younger pre-symptomatic carriers.
Drug repurposing (also called drug repositioning) searches existing FDA-approved drugs — medications already proven safe in humans for other indications — for activity against a new target. For ADLD, the ADLD Center is screening compounds that may reduce LMNB1 expression or protein levels as a secondary effect. Because safety data already exists for approved drugs, the path from identification to patient use is dramatically shorter than developing a novel compound: potentially 2–4 years rather than 8–12.
If a repurposed candidate is identified in 2026 or 2027, it could theoretically reach ADLD patients via off-label use or a fast-tracked compassionate use application before any novel therapy completes trials. The probability of finding a strong candidate is uncertain — most repurposing screens do not yield clinically useful hits — but the upside if they do is enormous given the compressed timeline.
A repurposed drug would follow the same pre-symptomatic preference as novel therapies. Its key advantage for younger at-risk individuals is speed: if identified soon, it could provide a bridging therapy while novel approaches complete their development.
Each of the five research programs has its own development path. Some milestones (like biomarker validation) benefit all programs; others are team-specific. The Mayo Clinic ASO program is the most advanced and sets the near-term pace for the field.
ADLD research isn't a single linear path — it's five parallel programs at different stages. If one program hits a setback, others continue independently. This redundancy is crucial for an ultra-rare disease. The Mayo ASO trial is furthest along, but the Padiath small molecule and Giorgio allele-silencing approaches could ultimately prove more practical for long-term treatment.
The publication of the Mayo Clinic N=1 trial safety and biomarker data (expected 2026–2027) is the hinge point for everything else. Positive data unlocks Phase 2 funding, regulatory dialogue, and trial expansion within 18–24 months.
A shared space for all families living with ADLD — post research updates, personal reflections, and resources. Every note is tagged by topic and the board is filterable so you can find what matters most. Notes are saved in your browser locally.